Stavudine

Generic Name
Stavudine
Brand Names
Zerit
Drug Type
Small Molecule
Chemical Formula
C10H12N2O4
CAS Number
3056-17-5
Unique Ingredient Identifier
BO9LE4QFZF
Background

A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.

Indication

For the treatment of human immunovirus (HIV) infections.

Associated Conditions
Human Immunodeficiency Virus (HIV) Infections
Associated Therapies
-

A Comparison of Zidovudine (AZT) and Stavudine in HIV-Infected Patients

Not Applicable
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2011-08-05
Lead Sponsor
Bristol-Myers Squibb
Registration Number
NCT00002307
Locations
🇺🇸

SUNY / Health Sciences Ctr at Stony Brook, Stony Brook, New York, United States

🇺🇸

East Bay AIDS Ctr, Berkeley, California, United States

🇺🇸

Children's Hosp of Los Angeles, Los Angeles, California, United States

and more 42 locations

A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection

First Posted Date
2001-08-31
Last Posted Date
2013-09-06
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
165
Registration Number
NCT00006154
Locations
🇨🇦

Centre Hospitalier de la Universite de Montreal (CHUM), Montreal, Quebec, Canada

🇨🇦

Centre de traitment d'immunodeficience, Montreal, Quebec, Canada

🇨🇦

Viridae Clinical Sciences / University of British Columbia, Vancouver, British Columbia, Canada

and more 1 locations

A Pilot Study to Compare the Antiviral and Immunologic Effects of Stavudine ( d4T ) Versus Placebo in Subjects With Evidence of Recent HIV Infection.

Not Applicable
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2011-04-14
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
40
Registration Number
NCT00002349
Locations
🇺🇸

Naval Med Ctr, Portsmouth, Virginia, United States

🇺🇸

Northwest Med Ctr, Seattle, Washington, United States

🇺🇸

San Diego Naval Hosp, San Diego, California, United States

A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment

Phase 1
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2021-10-29
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
217
Registration Number
NCT00000902
Locations
🇺🇸

Connecticut Children's Med Ctr, Farmington, Connecticut, United States

🇺🇸

Cedars Sinai / UCLA Med Ctr, Los Angeles, California, United States

🇺🇸

Harbor - UCLA Med Ctr / UCLA School of Medicine, Los Angeles, California, United States

and more 59 locations

Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen

Not Applicable
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2013-07-29
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
240
Registration Number
NCT00014937
Locations
🇮🇹

Spedali Civili - Carosi, Brescia, Italy

🇺🇸

Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States

🇺🇸

Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States

and more 34 locations

Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs

Phase 2
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2021-11-04
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
240
Registration Number
NCT00001083
Locations
🇺🇸

Harbor - UCLA Med Ctr / UCLA School of Medicine, Los Angeles, California, United States

🇺🇸

Univ of Miami (Pediatric), Miami, Florida, United States

🇺🇸

North Shore Univ Hosp, Great Neck, New York, United States

and more 58 locations

A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses

Phase 1
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2021-11-01
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
6
Registration Number
NCT00001108
Locations
🇺🇸

Cook County Hosp, Chicago, Illinois, United States

🇺🇸

Univ of Massachusetts Med School, Worcester, Massachusetts, United States

🇺🇸

Univ of Mississippi Med Ctr, Jackson, Mississippi, United States

and more 16 locations

Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs

Phase 2
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2011-05-04
Lead Sponsor
Bristol-Myers Squibb
Registration Number
NCT00002240
Locations
🇺🇸

AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States

🇺🇸

Albany Med College, Albany, New York, United States

🇺🇸

Clinsites / Sorra Research Ctr, Birmingham, Alabama, United States

and more 14 locations

A Study to Evaluate the Use of Stavudine (d4T) to Treat AIDS Dementia Complex

Phase 3
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2011-05-04
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
20
Registration Number
NCT00002246
Locations
🇺🇸

AIDS ReSEARCH Alliance, West Hollywood, California, United States

🇺🇸

Mount Sinai Hosp, New York, New York, United States

🇬🇧

Charing Cross and Westminster Med School, London SW 10, United Kingdom

and more 2 locations
© Copyright 2024. All Rights Reserved by MedPath